Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19) is a highly transmissible virus and has become pandemic. Part of the prevention of disease spread by the Malaysian government is by getting COVID-19 vaccine. Using the mRNA technology, the Pfizer/BioNTech vaccine is one of the vaccines been approved by the Drug Control Authority in Malaysia. Herein, we report an immediate complication of cerebral VST after the first dose of the Pfizer/BioNTech vaccine.
Introduction The world has had its eyes opened by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that started in December 2019 in Wuhan, Hubei, China. The World Health Organization (WHO) aptly changed the name to coronavirus disease 2019 (COVID-19), and since then, the infection has become a pandemic. In Malaysia, extensive measures have been taken to prevent the spread of COVID-19; however, we are dealing with a precarious situation due to the weakening economic growth [16]. The emergence of a promising anti-COVID-19 vaccine gives a platform of hope that the virus will soon abate [15]. The national vaccination program started on February 24, 2021 by the Drug Control Authority has approved three vaccines: COVID-19 vaccine AstraZeneca, CoronaVac suspension for injection (Sinovac), and Comirnaty concentrate for injection dispersion (Pfizer/BioNTech). The rapid development of vaccines comes with a setback as studies on long-term effects are still unproven. An emerging thromboembolic complication has been reported in hospitalized patients with COVID-19, with a rate of 21–32% [5, 9, 10]. The hypercoagulable state in those patients causes not only venous thromboembolism (VTE) [5, 7], but also cerebral venous sinus thrombosis (VST) [2], which can be fatal [4]. However, the risk of developing cerebral VST after receiving vaccination has never been reported, particularly in terms of the mRNA COVID-19 vaccine. Here, we report an immediate complication of cerebral VST after the first dose of the Pfizer/BioNTech vaccine.
Comentários